definiens: and ( each as defined in the Material Transfer Agreement ), and all other results, information, data, data a nalyses, reports, records, methods, processes, practices, fo rmulae, instructions, skills, techniques, procedure s, experiences and developments made by or on behalf of [COMPANY] in the course of conducting the Initial Development ( collectively, ) . For clarity, the SAS dataset from the Signal Fi nding Study will be included in the Initial Development Data . The Parti es will hold a telephonic or in person meeting at l east once each calendar quarter for sharing updates and discu ssing action plans on issues related to the Initial Development, including, but not limited to, the requalification of the Existing Clinical Material, the Signal Findi ng Study, and non - GMP process development . [COMPANY] will disclos e to KHK any clinical trial data from the Signal Fi nding Study received from the Children ’s Hospital of Phil adelphia ( ) promptly after [COMPANY] receives such data . [COMPANY] will maintain the Initial Developme nt Data in its database and will upon KHK ’s request, use good faith efforts to provide KHK with a copy or an elec tronic file of the Initial Development Data for KHK ’s use within * * * * * of receipt of such request . Additionally, upo n KHK ’s reasonable request, [COMPANY] will provide to KHK a copy or an electronic file of the topline data fr om the completed Signal Finding Study in its posses sion within * * * * * following receipt of such request . The toplin e data will consist of the summary tables of effica cy and safety, as defined in the Study Protocol, and will be compi led and prepared following database lock and all ne cessary QA / QC activities